McNeil Voluntarily Recalls Infants' Tylenol Oral Suspension Product - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

McNeil Voluntarily Recalls Infants' Tylenol Oral Suspension Product


ePT--the Electronic Newsletter of Pharmaceutical Technology

On Feb. 17, 2012, McNeil Consumer Healthcare, a division of McNeil-PPC, a subsidiary of Johnson & Johnson, voluntarily recalled approximately 574,000 bottles of its over-the-counter pain reliever and fever-reducer Infants’ Tylenol Oral Suspension, 1 oz. Grape. The voluntary recall was initiated after consumers complained of having difficulty using the SimpleMeasure dosing system.

The SimpleMeasure dosing system used for Infants’ Tylenol includes a dosing syringe that is inserted into a flow restrictor at the top of the bottle to measure dosage. Complaints were received from some consumers that the flow restrictor was pushed into the bottle when the syringe was inserted.

McNeil states, in a press release, that the voluntary recall was at the wholesale and retail level for seven lots distributed nationwide in the United States and that no adverse events have been reported. McNeil states that consumers may continue to use the product “provided that the flow restrictor at the top of the bottle remains in place,” but cautions consumers to not use the product if the flow restrictor is pushed into the bottle.

The specific lot numbers recalled were BIL0U00, BIL0V00, BIL3500, BJL2D00, BJL2E00, BJL2T00, BJL2U00, UPC Code 300450122308. Consumers can request a refund from McNeil by visiting www.tylenol.com.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here